MedTrace Logo

Faecal Analyses in Spondyloarthritis Therapy

NCT03839862 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-03-06

No results posted yet for this study

Summary

This study evaluates the intestinal microbiome and disease activity in patients with spondyloarthropathies receiving immunosuppressive therapy.

Patients will be analysed at two time points in reference to two predefined primary endpoints:

* Changes in intestinal microbiome
* Response to therapy

The investigators want to evaluate if successful treatment of spondylarthropathy coincide with specific changes in the gut flora.

Conditions

Interventions

DRUG

TNF-inhibition

Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Kristofer Andréasson, MD PhD · Lund University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03839862 on ClinicalTrials.gov